Business Irish

Wednesday 13 December 2017

Irish biotech firm bought in $15m deal

Genable is developing gene therapies for the treatment of dominant genetic diseases, including a condition that is a leading cause of inherited blindness.
Genable is developing gene therapies for the treatment of dominant genetic diseases, including a condition that is a leading cause of inherited blindness.
John Mulligan

John Mulligan

Irish biotechnology firm Genable Technologies has been acquired by US-based Spark Therapeutics in a deal understood to value it at $15m (€13.6m).

Genable is developing gene therapies for the treatment of dominant genetic diseases, including a condition that is a leading cause of inherited blindness. The treatment for that condition is called RhoNova.

Formerly known as Optigen, Genable was founded on the campus of Trinity College, Dublin, over a decade ago. Investors in the firm included Fountain Healthcare, Delta Partners, ACT, Enterprise Ireland, and Atlantic Bridge.

The latest set of publicly-available accounts for Genable, show that it had an accumulated loss of €7.8m at the end of February last year.

Spark Therapeutics has collaborated with Genable since 2014 in the development of RhoNova.

Irish Independent

Promoted Links

Business Newsletter

Read the leading stories from the world of Business.

Promoted Links

Also in Business